A federal appeals court has revived litigation linking acetaminophen to autism and ADHD, reversing a lower court's dismissal of the cases on scientific grounds.
The three-judge panel found that prior rulings rejecting the lawsuits based on unreliable science were premature. The decision clears a significant legal hurdle for plaintiffs who claim that prenatal or early childhood exposure to the painkiller caused neurodevelopmental disorders in their children.
The mass litigation against the drugmaker had stalled after a federal judge ruled the scientific evidence linking Tylenol to autism and ADHD was too weak to proceed. That determination effectively killed dozens of cases consolidated in multidistrict litigation.
The appellate court disagreed with that analysis, finding that the scientific record was sufficiently robust to allow the cases to move forward. The ruling does not resolve the underlying factual dispute about whether acetaminophen actually causes these conditions. Instead, it restores the plaintiffs' ability to pursue their claims through the discovery process and potentially at trial.
The decision marks a turning point for litigation that has struggled to gain traction against one of the world's most widely used over-the-counter medications. Tylenol makers face similar allegations in other courts, though most have been dismissed or are still in early stages.
Legal experts say the ruling could embolden additional claims and may prompt settlement discussions. The drugmaker has maintained that acetaminophen is safe when used as directed and that available evidence does not support a causal link to autism or ADHD.
Author James Rodriguez: "This is a critical juncture for a class of cases that nearly died on the vine."
Comments